Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder.
Platelet 3H-paroxetine binding measures were compared in three age-matched groups each containing 11 individuals: a group with DSM-III-R major depressive disorder (MDD) and comorbid obsessive-compulsive disorder (OCD), a group with DSM-III-R MDD alone, and a psychiatrically screened normal comparison group. No differences were found between groups in Bmax values. The patients with MDD only were found to have significantly higher Kd values than either the group with comorbid OCD or the normal subjects. No significant correlations were found between binding measures and either depressive or OCD symptoms. Our data suggest that inconsistencies remain in the literature on 3H-imipramine binding in OCD and that a variety of confounding factors may explain them. Duration of illness, for example, may be one such factor as decreases in uptake site number tend to dissipate with longer duration of illness.
Nelson
E C
EC
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110-1093, USA.
Sheline
Y I
YI
Bardgett
M E
ME
Jackson
J L
JL
Csernansky
J G
JG
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D015897:Comorbidity; D003866:Depressive Disorder / Q000097:blood* / Q000175:diagnosis / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000097:blood* / Q000175:diagnosis / Q000523:psychology; D017374:Paroxetine / Q000493:pharmacokinetics*; D011569:Psychiatric Status Rating Scales; D011955:Receptors, Drug / Q000378:metabolism*; D012701:Serotonin / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics*
D002352:Carrier Proteins; D017374:Paroxetine; D011955:Receptors, Drug; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; C092604:paroxetine receptor